Could early ibrutinib stop CLL before it starts?
NCT ID NCT03207555
First seen Sep 30, 2025 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This study tested whether giving the drug ibrutinib early to people with chronic lymphocytic leukemia (CLL) who have high-risk features but no symptoms yet is better than waiting until symptoms appear. Twenty-three participants took ibrutinib for up to 24 months. The goal was to see if early treatment could lead to complete or partial remission and delay disease progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASMS STATED AS PRIMARY LYMPHOID HAEMATOPOIETIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.